# Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients

> **NCT06754163** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **St Andrew's Healthcare** · enrollment: 20 (estimated)

## Conditions studied

- Obesity and Obesity-related Medical Conditions
- Psychiatric Disorders

## Interventions

- **DRUG:** Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)

## Key facts

- **NCT ID:** NCT06754163
- **Lead sponsor:** St Andrew's Healthcare
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754163, "Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06754163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*